Skip to main content
. 2020 Jul 28;32(4):107954. doi: 10.1016/j.celrep.2020.107954

Figure 2.

Figure 2

Effects of Diabetes and of Treatment with SGLT2i on RPTCs mTORC1 Activity

(A) Immunofluorescence staining for pS6 on kidney sections of 2-month-old wild-type and Akita mice.

(B) Immunofluorescence staining for YFP and pS6 in lineage-traced Sglt2-Cre;Rosa26-YFP+ reporter wild-type and Akita mice.

(C) Correlation coefficient of YFP and pS6 co-expression.

(D and E) pS6 fluorescence intensity (D) and (E) quantifications of RPTC area.

(F and G) Immunofluorescence staining for pS6 on kidney sections of streptozotocin (STZ)-induced diabetic mice and in db/db mice (F). Quantification of pS6 fluorescence intensity is shown in (G).

(H and I) Immunofluorescence staining for pS6 on kidney sections of wild-type and Akita mice treated with and without dapagliflozin for 12 weeks (H). Insets shown below are higher magnification of the area surrounded by a square; quantifications are shown in (I).

(J) Western blotting for pS6 on whole-kidney extracts of wild-type and Akita mice treated with and without dapagliflozin.

Scale bar, 50 μm. Data represent the mean ± SEM of six to eight mice per group. ∗p < 0.05 and ∗∗p < 0.01 relative to the wild-type control group; ##p < 0.01 relative to the untreated Akita mice group.